Results 1 to 10 of about 4,250 (56)

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Nature Biomedical Engineering, 2022
AbstractShort half-lives in circulation and poor transport across the blood–brain barrier limit the utility of cytokines and growth factors acting as receptor agonists. Here we show that surrogate receptor agonists with longer half-lives in circulation and enhanced transport rates across the blood–brain barrier can be generated by genetically inserting
Katsuya Sakai, Nozomi Sugano-Nakamura, Emiko Mihara, Nichole Marcela Rojas-Chaverra, Sayako Watanabe, Hiroki Sato, Ryu Imamura, Dominic Chih-Cheng Voon, Itsuki Sakai, Chihiro Yamasaki, Chise Tateno, Mikihiro Shibata, Hiroaki Suga, Junichi Takagi, Kunio Matsumoto   +14 more
openaire   +2 more sources

Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors [PDF]

Journal of Biological Chemistry, 2017
Multimeric fragment crystallizable (Fc) regions and Fc-fusion proteins are actively being explored as biomimetic replacements for IVIG therapy, which is deployed to manage many diseases and conditions but is expensive and not always efficient. The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structures (hexa-Fcs) that bind their ...
Patricia A. Blundell, Ngoc Phuong Lan Le, Joel Allen, Yasunori Watanabe, Richard J. Pleass   +4 more
openaire   +2 more sources

A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors [PDF]

, 2018
Engineering the fragment crystallizable (Fc) of human IgG can bring improved effector functions to monoclonal antibodies and Fc-fusion-based medicines and vaccines. Such Fc-effector functions are largely controlled by posttranslational modifications (PTMs) within the Fc, including the addition of glycans that introduce structural and functional ...
Patricia, Blundell, Richard, Pleass
openaire   +2 more sources

Choice of host cell line is essential for the functional glycosylation of the fragment crystallizable (Fc) region of human IgG1 inhibitors of influenza B viruses [PDF]

, 2019
AbstractAntibodies are glycoproteins that carry a conserved N-linked carbohydrate attached to the Fc, whose presence and fine structure profoundly impacts on theirin vivoimmunogenicity, pharmacokinetics and functional attributes. The host cell line used to produce IgG has a major impact on this glycosylation, as different systems express different ...
Blundell, Patricia A., Lu, Dongli, Dell, Anne, Haslam, Stuart M., Pleass, Richard J.   +4 more
openaire   +1 more source

Production and characterization of human soluble CD83 fused with the fragment crystallizable region of human IgG1 in Pichia pastoris

Applied Microbiology and Biotechnology, 2013
The cell surface protein CD83 belongs to the immunoglobulin superfamily and is highly expressed on mature dendritic cells. The soluble form of CD83, sCD83, is a potential immune suppressor. In a previous study, recombinant soluble CD83 was expressed in Escherichia coli, resulting in a lack of functional glycosylation.
Yuan, Y., Wan, L., Chen, Younan, Shi, M., Wang, C., Zhao, J., Lu, X., Wang, H., Lu, Y., Cheng, J.   +9 more
openaire   +3 more sources

3.5 Elevated Levels of Both Membrane-Bound and Soluble Forms of a Receptor Specific for the Fragment Crystallizable Region of Immunoglobulin M in Patients with CLL

Clinical Lymphoma Myeloma and Leukemia, 2011
3.5 Elevated Levels of Both Membrane-Bound and Soluble Forms of a Receptor Specific for the Fragment Crystallizable Region of Immunoglobulin M in Patients with CLL Fu Jun Li, Yoshiki Kubagawa, Matthew K. McCollum, Landon Wilson, Tomoko Motohashi, Luigi F. Bertoli, James C. Barton, Stephen Barnes, Randall S.
Fu Jun Li, Yoshiki Kubagawa, Matthew K. McCollum, Landon Wilson, Tomoko Motohashi, Luigi F. Bertoli, James C. Barton, Stephen Barnes, Randall S. Davis, Hiromi Kubagawa   +9 more
openaire   +1 more source

Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation. [PDF]

Clin Cancer Res
Pretelli G, Garralda E.
europepmc   +1 more source

Correction: The Evolution of Anti‑CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function. [PDF]

CNS Drugs
Cree BAC, Berger JR, Greenberg B.
europepmc   +1 more source

From Acute Carditis, Rheumatic Carditis, and Morphologic Cardiac Reactions to Allergic Angina, Allergic Myocardial Infarction, and Kounis Syndrome: A Multidisciplinary and Multisystem Disease. [PDF]

J Cardiovasc Dev Dis
Kounis NG, Stefanidis A, Hung MY, Özkan U, de Gregorio C, Ceasovschih A, Mplani V, Gogos C, Assimakopoulos SF, Chatzigrigoriadis C, Plotas P, Dousdampanis P, Kouni SN, Tsigkas G, Patsouras N, Calogiuri G, Pourmasumi S, Koniari I.   +17 more
europepmc   +1 more source

Advantages of MabSelect VH3, a novel VH3-specific Protein A resin, over its two conventional counterparts in purifying a VHH-based trispecific antibody. [PDF]

J Biol Methods
Fang D, Qi W, Li Y.
europepmc   +1 more source